TITLE

Recently Approved

PUB. DATE
June 2008
SOURCE
Pharmaceutical Representative;Jun2008, Vol. 38 Issue 6, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents news briefs on drug approval in North America. A once-monthly does of the 150 mg Actonel tablets has been approved for the treatment and prevention of postmenopausal osteoporosis. Ontario-based Biovail Corp. has received approval from the Food and Drug Administration for its Aplenzin for the treatment of depression in adults. The marketing authorization for Relistor (methylnaltrexone bromide), developed by Progenics Pharmaceuticals and Wyeth Pharmaceuticals, was approved.
ACCESSION #
32429551

 

Related Articles

  • New drug helps palliative patients on opioids take care of business. Fernandez, Julio // Drug Topics;6/16/2008, Vol. 152 Issue 7, Special section p2 

    The article announces the approval of the U.S. Food and Drug Administration of Relistor, methylnaltrexone bromide, for the treatment of palliative patients on opioids. The drug, which manufactured by Progenics Pharmaceuticals and Wyeth Pharmaceuticals, has been approved for the treatment of...

  • Wyeth Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for DURACT Capsules. Woodcock, Janet // Federal Register (National Archives & Records Service, Office of;7/9/2012, Vol. 77 Issue 131, p40367 

    The article presents a notice from the U.S. Food and Drug Administration (FDA) on its withdrawal of the approval of a drug application of Wyeth Pharmaceuticals Inc. for DURACT Capsules as requested by Wyeth.

  • FDA Approves Amgen's Prolia for Treatment of Postmenopausal Women with Osteoporosis.  // BioPharm International;Jul2010, Vol. 23 Issue 7, p14 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Prolia, a postmenopausal treatment for women with osteoporosis at high risk for fracture, manufactured by Thousand Oaks, California-based Amgen Inc.

  • Decisions Update.  // PharmaWatch: Biotechnology;Sep2006, Vol. 5 Issue 9, p17 

    The article reports developments on the drug applications of several pharmaceutical companies to the U.S. Food and Drugs Administration (FDA) in 2006. The FDA has granted fast track status to Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc.'s intravenous form of methylnaltrexone being...

  • pharmaceuticals In Brief.  // Chemical Market Reporter;5/10/2004, Vol. 265 Issue 19, p10 

    Reports on news and developments concerning the pharmaceutical industry in the United States. U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee's disapproval of Allos Therapeutics Inc.'s investigational radiation sensitizer RSR13 for the treatment of patients with brain...

  • Progenics gets sNDA for Opioid-Induced Constipation.  // Biotech Business;Aug2011, Vol. 24 Issue 8, p6 

    The article focuses on Progenics Pharmaceuticals' supplemental New Drug Application submission to the U.S. Food and Drug Administration for the approval of RELISTOR, which is a drug that is meant to treat the underlying cause of opioid-induced constipation (OIC). The drug is already used in the...

  • FDA OKs Progenics Drug; EMA also Gives It a Nod. Hollingsworth, Catherine // BioWorld Today;4/28/2008, Vol. 19 Issue 82, p1 

    The article announces that the Relistor drug, developed by Progenics Pharmaceuticals Inc. for constipation, has been approved by the U.S. Food & Drug Administration (FDA). This marks the company's first approved product in the country, triggering a $15 million milestone payment from partner...

  • FDA OKs Progenics Drug; EMEA Decision Soon.  // Bioworld Week;5/5/2008, Vol. 16 Issue 18, p2 

    The article reports on the FDA approval of Progenics Pharmaceuticals Inc.'s Relistor (methyl-naltrexone bromide) for constipation due to the use of powerful painkillers in patients with incurable cancer and other advanced-stage diseases. The decision marks Progenics' first U.S. approved product,...

  • Solvay and Wyeth: potential blockbuster submitted for approval.  // PharmaWatch: CNS;Nov2006, Vol. 5 Issue 11, p11 

    The article reports that an application has been filed by Solvay Pharmaceuticals Inc. and Wyeth Pharmaceuticals to the U.S. Food and Drug Administration. The application refers to a new schizophrenia treatment by the use of bifeprunox. To check its safety and efficacy, antipsychotic bifeprunox...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics